



LARRY HOGAN
Governor

BOYD K. RUTHERFORD
Lieutenant Governor

DAVID R. BRINKLEY
Secretary

MARC L. NICOLE
Deputy Secretary

QUESTIONS AND RESPONSES # 7
PROJECT NO. F10B640005R
Department of Budget & Management
Pharmacy Benefit Management Services and Pharmacy Benefits
Purchasing Pool Management
June 17, 2016

Ladies/Gentlemen:

This List of Questions and Responses #7, question #90, is being issued to clarify certain information contained in the above named RFP.

In most instances the Department's response to the submitted questions merely serves to clarify the existing requirements of the RFP. Sometimes, however, in submitting questions potential Offerors may make statements or express interpretations of contract requirements that may be inconsistent with the Department's intent. To the extent that the Department recognizes such an incorrect interpretation, the provided answer will note that the interpretation is erroneous and either state that the question is moot once the correct interpretation is explained or provide the answer based upon the correct interpretation.

No provided answer to a question may in and of itself change any requirement of the RFP. If it is determined that any portion of the RFP should be changed based upon a submitted question, the actual change may only be implemented via a formal amendment to the RFP. In this situation the answer provided will reference the amendment containing the RFP change.

Questions and Answers

90. Is it possible to receive updated claims data for Q1 2016, specifically for the Hepatitis C drug class? The active/pre-65 retiree claims data for 2015 for the Hepatitis C drug class shows an increase on a quarterly basis in utilization of this category, whereas most clients are seeing a decrease in utilization from highs in late 2014/early 2015, and this is showing the retiree claims data for the State as well. Since this drug class can have a large impact on rebate assumptions for specialty products, it would be ideal to receive updated claims data showing recent utilization in the category.

RESPONSE: The Department has made Q1 2016 claims data for the Hepatitis C drug class available. The confidential data has been sent via secure file transfer to all vendors who submitted a Non-Disclosure Agreement to the Procurement Officer in order to receive the confidential documents required to propose. Potential Offerors who did not receive the updated Hepatitis C claims data are instructed to contact the Procurement Officer to ensure receipt.